Genentech taps small Boston pharma in $20M respiratory, eye drug research deal

Pieris Pharmaceuticals, a small biotech behind a suite of engineered proteins it calls anticalins, has signed a major research and development deal with Genentech for respiratory and ophthalmology treatments.

Click to view original post